Suppr超能文献

中高剂量口服泼尼松龙与低中剂量肌内注射促肾上腺皮质激素改善韦斯特综合征中高度节律失调的疗效:一项随机、单盲、平行临床试验。

The efficacy of moderate-to-high dose oral prednisolone versus low-to-moderate dose intramuscular corticotropin for improvement of hypsarrhythmia in West syndrome: a randomized, single-blind, parallel clinical trial.

作者信息

Wanigasinghe Jithangi, Arambepola Carukshi, Sri Ranganathan Shalini, Sumanasena Samanmali, Muhandiram Eindrini C

机构信息

Department of Pediatrics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.

Department of Community Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.

出版信息

Pediatr Neurol. 2014 Jul;51(1):24-30. doi: 10.1016/j.pediatrneurol.2014.03.014. Epub 2014 Mar 22.

Abstract

BACKGROUND

The role of therapy on improvement of hypsarrhythmia has not been systematically assessed. This study was performed to assess the efficacy of oral prednisolone and intramuscular adrenocorticotrophin hormone in improving hypsarrhythmia in West syndrome.

METHOD

Children (2 months-2 years), with previously untreated West syndrome, were randomized to receive 40-60 IU every other day of intramuscular adrenocorticotrophin hormone or 40-60 mg/day of oral prednisolone for 14 days. Children with tuberous sclerosis were excluded. Improvement of hypsarrhythmia was assessed blindly using a hypsarrhythmia severity scale before and after completion of therapy. Adverse effects were assessed on day 14 using symptom diary. (Clinical trial registry identifier: SLCTR/2010/010.)

RESULTS

From 92 newly diagnosed West syndrome infants, 48 were randomized to receive prednisolone and 44 to receive adrenocorticotrophin hormone. Eighty infants completed the posttreatment evaluation according to specifications. The hypsarrhythmia severity score, significantly improved with hormonal therapy for 2 weeks (10.45 ± 2.65 vs 3.45 ± 2.67); P < 0.01. When individual treatment arms were compared using mean differences in the improvement of scores, improvement in prednisolone arm (7.95 ± 2.76) was significantly greater than that in the adrenocorticotrophin hormone arm (6.00 ± 2.61); P < 0.01. Both forms of therapy were tolerated well. Frequent crying, irritability, weight gain, increased appetite, and abdominal distension were more common (but not statistically significant) with prednisolone.

CONCLUSIONS

Hypsarrhythmia severity score improved significantly with both hormonal therapies, but this improvement was significantly better with oral prednisolone than intramuscular adrenocorticotrophin hormone. This is the first ever documentation of a superior therapeutic role of oral steroids in West syndrome.

摘要

背景

治疗对婴儿痉挛症改善作用尚未得到系统评估。本研究旨在评估口服泼尼松龙和肌内注射促肾上腺皮质激素对改善韦斯特综合征婴儿痉挛症的疗效。

方法

将先前未经治疗的韦斯特综合征患儿(2个月至2岁)随机分组,隔日肌内注射促肾上腺皮质激素40 - 60 IU或口服泼尼松龙40 - 60 mg/天,共14天。排除结节性硬化症患儿。治疗结束前后采用婴儿痉挛症严重程度量表对婴儿痉挛症改善情况进行盲法评估。在第14天使用症状日记评估不良反应。(临床试验注册标识符:SLCTR/2010/010。)

结果

92例新诊断的韦斯特综合征婴儿中,48例随机接受泼尼松龙治疗,44例接受促肾上腺皮质激素治疗。80例婴儿按要求完成了治疗后评估。经2周激素治疗后,婴儿痉挛症严重程度评分显著改善(10.45±2.65对3.45±2.67);P<0.01。使用评分改善的平均差异比较各治疗组时,泼尼松龙组(7.95±2.76)的改善显著大于促肾上腺皮质激素组(6.00±2.61);P<0.01。两种治疗方式耐受性均良好。泼尼松龙治疗时,频繁哭闹、易激惹、体重增加、食欲增加和腹胀更为常见(但无统计学意义)。

结论

两种激素治疗均使婴儿痉挛症严重程度评分显著改善,但口服泼尼松龙的改善效果显著优于肌内注射促肾上腺皮质激素。这是首次记录口服类固醇在韦斯特综合征中具有更优治疗作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验